Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indevus buoyed by positive trial data
Sanctura XR is the once-daily formulation of Sanctura, which the company has marketed for overactive bladder for nearly two years. The data from the recently completed trial showed
Sanctura XR is the once-daily formulation of Sanctura, which the company has marketed for overactive bladder for nearly two years. The data from the recently completed trial showed
These microRNAs are to be added to Rosetta’s microRNA database, providing the company with additional biomarker candidates for its diagnostic development programs. Under the terms of the agreement,
Favrille now intends to initiate a phase I/II clinical trial evaluating the safety and biologic activity of FAV-201 in patients with cutaneous T-cell lymphoma. The trial will build
The two phase III clinical studies, known as GOUT 1 and GOUT 2, are designed to compare the safety and efficacy of Puricase administered by two-hour intravenous infusion
The study, published in Molecular Immunology, describes one of the first human antibodies potently neutralizing human GM-CSF. GM-CSF is a key pro-inflammatory cytokine responsible for the proliferation, activation,
Istaroxime was identified, patented and developed up to phase I by Italian pharmaceutical company Sigma-Tau. Under the terms of the agreement, Debiopharm has the right to develop and
The compound won the designation for the prevention and/or treatment of delayed graft function (DGF) after solid organ transplantation and the treatment of capillary leakage syndrome (CLS). Delayed
This trial is being sponsored by the National Cancer Institute (NCI) under a clinical trials agreement with CuraGen for PXD101, a small molecule histone deacetylase (HDAC) inhibitor. The
The findings from the study, part of a larger, double-blind, placebo-controlled, randomized trial conducted over 14 weeks, specifically showed that liraglutide increased the maximum capacity of beta cells
The patients being enrolled in the trial have chronic, accelerated and blast-phase chronic myeloid leukemia (CML) and have the T315I bcr-abl point mutation, which is associated with resistance